The data presented here suggested that survivin and p-survivin expression could provide a comparatively better alternative for the stratification of HCC patients for treatment with YM155 in novel biomarker-driven therapeutic strategies. The gene discussed is BIRC5; the disease is hepatocellular carcinoma.